Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.71 |
| ▸ | CNR1 | P21554 | 6/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4576062 | 0.99 | CNR2 (0.69) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL5097779 | 0.89 | CNR2 (0.67) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1929381 | 0.87 | CNR2 (0.72) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1928747 | 0.85 | CNR2 (0.71) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL4037941 | 0.83 | CNR2 (0.50) | CNR2CNR1PTGS2PTGS1 | |
| SCHEMBL1926401 | 0.83 | CNR2 (0.67) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL1927474 | 0.83 | CNR2 (0.67) | CNR2CNR1PTGS2PTGS1CA1 | |
| SCHEMBL2348536 | 0.83 | CNR2 (1.00) | CNR2CNR1PTGS2PTGS1CA1 | |
| Hydrochloric Acid SCHEMBL1927169 | 0.82 | CNR2 (0.97) | CNR2CNR1PTGS2PTGS1CA1 | |
| Hydrochloric Acid SCHEMBL1928142 | 0.82 | CNR2 (0.66) | CNR2CNR1PTGS2PTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904063-B1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT | IPSEN PHARMA (FR) | 2019-02-20 | — | — | EP | claimed |
| US-9918967-B2 | Thiazole derivatives for treating dyskinesias caused by a chemical treatment | IPSEN PHARMA S.A.S. (FR) | 2018-03-20 | — | — | US | claimed |
| US-20150238468-A1 | THIAZOLE DERIVATIVES FOR TREATING DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT | IPSEN PHARMA S.A.S. (FR) | 2015-08-27 | — | — | US | claimed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | claimed |
| JP-2012500283-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110190356-A1 | Compositions and Methods of Using (R)- Pramipexole | KNOPP NEUROSCIENCES INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | claimed |
| EP-2334185-A1 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE | Knopp Neurosciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | claimed |
| WO-2010022140-A1 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE | KNOPP NEUROSCIENCES, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| WO-2007006941-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF RESTLESS LEGS SYNDROME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-01-18 | — | — | WO | claimed |
| WO-2007006942-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2007-01-18 | — | — | WO | claimed |
| EP-1223933-B1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINOXIDASE INHIBITORS | SOD CONSEILS RECH APPLIC (FR) | 2006-09-06 | — | — | EP | claimed |
| EP-1414447-B1 | USE OF THIAZOLE DERIVATIVES FOR PREPARING A MEDICINE FOR PROTECTING MITOCHONDRIA | SOD CONSEILS RECH APPLIC (FR) | 2006-07-26 | — | — | EP | claimed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | claimed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | claimed |
| EP-1414447-A1 | USE OF THIAZOLE DERIVATIVES FOR PREPARING A MEDICINE FOR PROTECTING MITOCHONDRIA | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-05-06 | — | — | EP | claimed |
| WO-2003009843-A1 | USE OF THIAZOLE DERIVATIVES FOR PREPARING A MEDICINE FOR PROTECTING MITOCHONDRIA | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-02-06 | — | — | WO | claimed |
| EP-1223933-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-24 | — | — | EP | claimed |
| WO-2001026656-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | CNR2 22/4885CNR1 13/4885PTGS2 364/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | CNR2 15/4885CNR1 5/4885PTGS2 366/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | CNR2 27/4885CNR1 17/4885PTGS2 427/4885 |
| US-20150238468-A1 | THIAZOLE DERIVATIVES FOR TREATING DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT | COMT, SLC6A3, PARK7 | CNR2 846/4885CNR1 1172/4885PTGS2 1019/4885 |
| US-20110190356-A1 | Compositions and Methods of Using (R)- Pramipexole | HSPE1, GRIN2B, GRIN2A | CNR2 3952/4885CNR1 4093/4885PTGS2 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.